United States v. Daniel Gwin
Opinion
NOT RECOMMENDED FOR PUBLICATION File Name: 24a0120n.06
No. 23-3465
FILED
UNITED STATES COURT OF APPEALS Mar 14, 2024 FOR THE SIXTH CIRCUIT
KELLY L. STEPHENS, Clerk
)
UNITED STATES OF AMERICA, ) ON APPEAL FROM THE
Plaintiff-Appellee, ) UNITED STATES DISTRICT ) COURT FOR THE v. ) NORTHERN DISTRICT OF ) OHIO
DANIEL GWIN, )
Defendant-Appellant. ) OPINION )
Before: COLE, CLAY, and BLOOMEKATZ, Circuit Judges.
BLOOMEKATZ, Circuit Judge. In 2022, Daniel Gwin pleaded guilty to nine felony counts stemming from his role in a conspiracy at his workplace. Gwin was a manager at a family-owned medical research center that we refer to as “Company 1.” Gwin, along with seven other Company 1 employees, fabricated the results of clinical trials for recently developed medications, which pharmaceutical companies then presented to federal regulators in seeking approval to make these new drugs available to the public.
The district court sentenced Gwin to a below-guidelines sentence of 30-months’
imprisonment. Gwin claims that this sentence was both procedurally and substantively unreasonable, arguing that the district court did not sufficiently explain why it sentenced him to several more months than two of his coconspirators, and that it did not adequately weigh the mitigating factors which, in his view, mandated a lesser sentence. Because the district court did not abuse its discretion in sentencing Gwin, we affirm.
FACTUAL BACKGROUND
In 2012, Daniel Gwin began a position as a study coordinator at Company 1. Company 1 was a research organization owned by Amie Demming and Debra Adamson—a mother and daughter team—with offices in Ohio and Tennessee. The company employed multiple family members, including William and Ashley Adamson, but Gwin was not related. Company 1 conducted FDA-required clinical trials of investigative drugs for pharmaceutical companies. Clinical trials are necessary to ensure that a pharmaceutical company’s new drug is safe and effective for human use. As a study coordinator in the Cleveland-area office, Gwin was responsible for managing the trials for various of Company 1’s clients, and in doing so he supervised other research employees.
The conspiracy began in 2013, about six months after Gwin took the job. Demming was the ringleader and developed the scheme when the company began to face financial troubles. Gwin states that Demming harassed, bullied, and intimidated him, and that he feared losing his job if he did not participate in the scheme.
The scheme, roughly described, was as follows: Company 1 employees falsely inflated the number of research participants in the clinical trials, then Company 1 billed its clients for the nonexistent work. Gwin and his colleagues fabricated test subjects from whole cloth, registered patients for studies without consent, falsified laboratory results, and collected payment for each phony participant. At times, Gwin even substituted his own blood and medical information for that of real study participants. As a study coordinator, Gwin signed informed consent forms for other employees who fraudulently registered themselves in clinical trials. Company 1 sent these false clinical results to its pharmaceutical clients, who then submitted the results to the FDA in seeking approval that their drugs were safe and effective.
Because Gwin’s claim rests on the alleged sentencing disparity with his coconspirators, we describe not only his culpability, but also that of William and Ashley Adamson, whom Gwin points to as the most relevant comparators. William and Ashley Adamson were Amie Demming’s brother and sister-in-law, and they managed the Tennessee offices.
The three employees were responsible for similar amounts of economic loss. During the course of the conspiracy, eight pharmaceutical companies paid Company 1 a total of $6,552,903 for—unbeknownst to them—fraudulent clinical trials. Gwin was personally responsible for little over $2.8 million of that amount, the third highest of the defendants. William Adamson caused $2.72 million in loss and Ashley Adamson caused $2.94 million in loss.
The three employees were also paid under a similar compensation structure. Company 1 paid Gwin and the Adamsons an annual salary and a year-end bonus. The bonus was based on the company’s profits and the employee’s individual performance, which was tied to the number of patients the employee enrolled in studies. Gwin had a starting salary of $43,500, and Ashley Adamson, who began around the same time, had a starting salary $41,600. No party argued that their salaries differed markedly in subsequent years. In their first years, Gwin and Ashley Adamson received bonuses of $500 and $1,800, respectively, while the next year they received $1,500 and $1,800, respectively.
The three employees’ pleas, however, looked different. The Adamsons pleaded guilty to one count of conspiracy to commit mail fraud and wire fraud. The district court sentenced William to 22 months’ imprisonment and Ashley to 27 months.
Gwin pleaded guilty to nine counts—one count of conspiracy to commit mail fraud and wire fraud, seven counts of mail fraud, and one count of conspiracy to defraud the United States. At sentencing, the court granted Gwin a three-level reduction for acceptance of responsibility.
That, combined with Gwin’s lack of criminal history, resulted in a range of 33 to 41 months under the Sentencing Guidelines. After weighing the aggravating and mitigating factors, the district court varied downward, giving Gwin a below-guidelines sentence of 30-months in prison followed by three years of supervised release, a mandatory $900 special assessment, and $2,841,792 in restitution.
ANALYSIS
On appeal, Gwin argues that his sentence was both procedurally and substantively unreasonable. We review both his procedural and substantive reasonableness claims for an abuse of discretion. Gall v. United States, 552 U.S. 38, 41 (2007).1 We address each challenge in turn.
I. Procedural Reasonableness In reviewing whether a sentence was procedurally unreasonable, we look to see whether
the district court “(1) properly calculated the applicable advisory Guidelines range; (2) considered the other § 3553(a) factors as well as the parties’ arguments for a sentence outside the Guidelines range; and (3) adequately articulated its reasoning for imposing the particular sentence chosen, including any . . . decision to deviate from the advisory Guidelines range” or rejection of the parties’ arguments that it should deviate. United States v. Bolds, 511 F.3d 568, 581 (2007).
Gwin urges us to reverse on the third requirement, arguing that the district court did not adequately articulate why he received a longer sentence than either William or Ashley Adamson. He emphasizes that he received the second highest sentence in the conspiracy—just behind
1 The government urges us to review the procedural reasonableness claim for plain error rather than for an abuse of discretion because it says that Gwin did not adequately preserve his objection at the sentencing hearing. We need not decide the preservation question because Gwin’s challenge fails even when we review for an abuse of discretion, as we do when an objection is adequately preserved.
Demming, the leader—even though his calculated loss was less than Ashley Adamson’s (27 months), and he did not substantially benefit from the conspiracy because he was not a family member, like William Adamson (22 months). He characterizes the district court’s analysis as disregarding his culpability relative to his coconspirators. But that’s not accurate.
Free access — add to your briefcase to read the full text and ask questions with AI
United States v. Daniel Gwin (United States v. Daniel Gwin) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.